Emergency team-response simulator for malignant hyperthermia: recognition, MH cart activation, dantrolene reconstitution/dosing, cooling, and post-crisis workup
Malignant hyperthermia (MH) is a life-threatening pharmacogenetic disorder of skeletal muscle triggered by volatile anesthetics (sevoflurane, desflurane, isoflurane) and the depolarizing muscle relaxant succinylcholine. In susceptible individuals — most commonly carrying a mutation in the RYR1 ryanodine receptor gene — exposure precipitates uncontrolled calcium release from the sarcoplasmic reticulum, sustained muscle contraction, and a runaway hypermetabolic state. Early recognition and immediate cessation of triggering agents are the single most time-critical actions in the entire protocol.
MH susceptibility arises predominantly from mutations in RYR1, the gene encoding the skeletal muscle ryanodine receptor — the calcium release channel of the sarcoplasmic reticulum (SR). Roughly 50–70% of MH-susceptible families carry an identifiable RYR1 variant; a smaller subset carry mutations in CACNA1S (the dihydropyridine receptor) or STAC3. These mutations destabilize the closed state of the channel, so that exposure to a volatile anesthetic or succinylcholine causes massive, sustained calcium efflux from the SR into the sarcoplasm.
The consequences cascade rapidly: sustained actin-myosin cross-bridge cycling causes sustained muscle contraction (rigidity), consuming ATP at an extraordinary rate. Aerobic metabolism cannot keep pace, so anaerobic glycolysis surges, producing lactate and CO₂ far in excess of normal ventilation, and heat production skyrockets — a true hypermetabolic crisis, not a primary "fever." Cellular energy failure eventually causes membrane breakdown, releasing potassium, myoglobin, and creatine kinase into the circulation.
MH is fundamentally a disorder of calcium handling, not of thermoregulation — the dramatic temperature rise is a downstream consequence of uncontrolled muscle metabolism, which is why the definitive treatment (dantrolene) targets the ryanodine receptor rather than cooling alone.
MH can present abruptly or evolve over 30–60 minutes after trigger exposure. No single sign is diagnostic; the pattern and trajectory matter more than any isolated value.
• Rising end-tidal CO₂ (EtCO₂): often the earliest and most sensitive sign — a progressive rise despite unchanged minute ventilation, sometimes exceeding 2x the fresh-gas-flow-adjusted baseline • Unexplained tachycardia and tachypnea (in a spontaneously breathing patient) • Masseter muscle rigidity after succinylcholine — trismus that prevents jaw opening, a strong red flag especially in pediatric anesthesia • Generalized muscle rigidity, often delayed relative to the metabolic signs • Rising core temperature — classically a late sign; temperature can climb 1–2°C every 5 minutes once established • Mixed respiratory and metabolic acidosis on blood gas • Cyanosis or mottling, tachyarrhythmias, and dark/cola-colored urine from myoglobinuria in later stages
Because early signs mimic light anesthesia or equipment problems, a structured index of suspicion — checking capnography trend, not just an isolated reading — is essential.
The moment MH is suspected, action must precede complete diagnostic certainty, because delay is directly linked to mortality.
1. Stop all volatile anesthetic agents and succinylcholine immediately 2. Call for help out loud — announce "malignant hyperthermia" so the team can mobilize the MH cart and additional hands 3. Switch to total intravenous anesthesia (TIVA) if the case must continue 4. Increase fresh gas flow and begin hyperventilation with 100% oxygen to wash out residual volatile agent and address the rising CO₂ 5. Assign a dedicated team member to call the MH hotline for real-time expert guidance while treatment proceeds 6. Notify the surgical team; the procedure should be expedited to conclusion or aborted if feasible without compromising the patient
Every anesthetizing location that stocks volatile agents or succinylcholine is expected to maintain an immediately accessible MH cart stocked with dantrolene, sterile water, and the supplies needed for the steps that follow.
While one team member hyperventilates the patient on 100% oxygen at maximal fresh gas flow, the rest of the response team activates the malignant hyperthermia cart. The most labor-intensive early task is reconstituting dantrolene — historically a slow, multi-person process because each 20 mg vial of conventional dantrolene sodium requires roughly 60 mL of sterile (preservative-free) water and vigorous agitation to dissolve, and a full weight-based dose can require twenty or more vials.
Switching to 100% oxygen at 2–3x normal fresh gas flow accomplishes two things simultaneously: it flushes residual volatile anesthetic from the breathing circuit and the patient's tissues, removing the ongoing trigger, and it maximizes oxygen delivery to tissues whose metabolic demand has surged far above normal. Minute ventilation should be increased substantially (often doubled) to manage the sharply elevated CO₂ production; a soda-lime CO₂ absorber and fresh circuit or a dedicated MH-clean anesthesia machine (or manual bagging) may be used if immediate switch to a decontaminated machine is impractical, since volatile agent can persist in machine components for extended periods.
A well-stocked MH cart is organized in labeled drawers so any team member, even one unfamiliar with the specific unit, can find supplies quickly under stress:
• Dantrolene supply: at least 36 vials (enough for ~10 mg/kg in a 70 kg adult with conventional formulation), sterile preservative-free water for injection, large syringes • Cooling supplies: ice packs, cold saline for IV and irrigation, cooling blankets, nasogastric/bladder lavage kits • Medications for hyperkalemia and arrhythmias: regular insulin, dextrose, calcium chloride/gluconate, sodium bicarbonate, amiodarone • Monitoring supplies: arterial line kit, urinary catheter, temperature probes • A laminated copy of the MH treatment algorithm and the MH hotline number posted prominently
One or two staff members are typically assigned solely to dantrolene reconstitution so the rest of the team can manage the airway, circulation, and cooling in parallel — MH response is fundamentally a team choreography exercise, not a single clinician's task.
Conventional dantrolene sodium (Dantrium/Revonto) ships as a lyophilized orange powder, 20 mg per vial, that must be reconstituted with 60 mL of sterile water for injection (without a bacteriostatic agent, since benzyl alcohol is contraindicated at MH doses in some formulations). The powder dissolves slowly and requires vigorous, sustained shaking — a single vial can take close to a minute, and treating a 70 kg adult to 2.5 mg/kg requires roughly nine vials for the first bolus alone, more if repeat doses are needed.
Newer nanocrystalline suspension formulations (e.g., Ryanodex) dramatically shorten this step: each 250 mg vial reconstitutes in only about 5 mL of sterile water and dissolves within roughly 20 seconds of shaking, meaning a full weight-based dose can be prepared from a single vial rather than dozens. Regardless of formulation, reconstitution should proceed in parallel across multiple team members working multiple vials simultaneously, since the time from recognition to first dantrolene dose is one of the strongest modifiable predictors of outcome.
A useful working figure for planning: treating a 70 kg adult to the initial 2.5 mg/kg dose requires about 175 mg of dantrolene — roughly nine 20 mg conventional vials (540 mL of sterile water) or a single 250 mg nanocrystalline vial reconstituted in 5 mL.
Dantrolene sodium is the only pharmacologic agent proven to reverse the malignant hyperthermia crisis, and it must be given as soon as it is available rather than waiting for full cart preparation. The initial dose is 2.5 mg/kg IV, pushed rapidly, and repeated every 5–10 minutes as needed, titrating against falling EtCO₂, heart rate, and rigidity rather than against a fixed ceiling — most patients respond within the first 10 mg/kg, though larger cumulative doses are occasionally required.
Dantrolene is a hydantoin derivative that acts directly on the ryanodine receptor type 1 (RyR1) in skeletal muscle sarcoplasmic reticulum, binding near the channel's regulatory domain and stabilizing its closed conformation. This suppresses the pathologic, sustained calcium efflux that drives the MH hypermetabolic state without paralyzing the muscle or requiring the mutation to be corrected — dantrolene works regardless of which specific RYR1 variant is present, because it targets channel gating rather than the mutation itself. Unlike neuromuscular blockers, dantrolene reduces excitation-contraction coupling at the level of calcium release rather than at the neuromuscular junction, which is why it can relax the sustained muscle rigidity of MH while leaving voluntary neuromuscular transmission largely intact at therapeutic doses.
After the initial 2.5 mg/kg bolus, the team reassesses EtCO₂ trend, heart rate, rigidity, and temperature trajectory before deciding on a repeat dose, typically every 5–10 minutes. There is no absolute dose ceiling in an ongoing crisis — published protocols describe cumulative doses well beyond 10 mg/kg in refractory cases — but most patients begin to show a measurable response (falling EtCO₂, softening rigidity, slowing heart rate) within the first two to four doses.
Signs that further dosing is needed include persistently rising or plateaued EtCO₂, ongoing rigidity, recurrent tachyarrhythmia, or a temperature that continues to climb. Signs supporting adequate dosing include a sustained downtrend in EtCO₂ and heart rate, resolution of rigidity, and temperature turning the corner toward normal. Because dantrolene is prepared in a large volume of diluent, IV access and infusion capacity should be secured early so repeat doses are not bottlenecked by reconstitution rather than by clinical need.
Dosing regimen: dantrolene 2.5 mg/kg IV push initially, repeated every 5–10 minutes as needed until EtCO₂, heart rate, and rigidity trend toward normal — commonly requiring a cumulative 4–10 mg/kg, with no fixed maximum in a persisting crisis. When in doubt, the MH hotline (staffed by MH experts around the clock) is available for real-time dosing and management guidance during an active event.
Dantrolene is markedly alkaline (pH ~9.5) and irritating to peripheral veins; a large-bore IV or central access is preferred when available, and the line should be flushed well afterward. Because reconstituted dantrolene does not contain a preservative, freshly mixed solution should be used promptly, and any conventional-formulation vials not immediately needed can be prepared in parallel by additional staff so doses are ready before they are called for. Ongoing doses should not be delayed to wait for a "complete" reconstitution of the full anticipated total dose — administering available reconstituted drug immediately, while more is prepared in parallel, keeps the treatment timeline as short as possible.
Dantrolene addresses the underlying calcium leak, but the hypermetabolic crisis also demands aggressive supportive care in parallel: active cooling to control hyperthermia, correction of the hyperkalemia and acidosis produced by the metabolic surge, arrhythmia monitoring, and protection of the kidneys against the myoglobin released by breaking-down muscle. These measures run concurrently with dantrolene dosing rather than sequentially after it.
Cooling is applied wherever heat exchange is efficient: ice packs to the axillae, groin, and neck (over major vessels), cold IV crystalloid, cooling blankets or forced-air cooling devices, and — for refractory hyperthermia — cold gastric, bladder, peritoneal, or even chest lavage in extreme cases. Cooling should be stopped once core temperature approaches roughly 38.5°C to prevent overshoot into hypothermia, since temperature can continue drifting down after active cooling is discontinued. Surface cooling is combined with the systemic cooling effect of dantrolene itself, since arresting the hypermetabolic contracture directly reduces ongoing heat production — cooling alone, without dantrolene, does not address the underlying process.
Massive muscle breakdown releases potassium rapidly, and combined with acidosis this creates real risk of life-threatening arrhythmia. Standard treatment mirrors general hyperkalemia management:
• Regular insulin (10 units) with dextrose (50 mL of D50, with glucose monitoring) to shift potassium intracellularly • Calcium chloride or calcium gluconate to stabilize the cardiac membrane when ECG changes or significant hyperkalemia are present • Sodium bicarbonate to correct significant metabolic acidosis, guided by blood gas • Hyperventilation, already underway, helps address the respiratory component of the mixed acidosis • Standard antiarrhythmics (e.g., amiodarane per ACLS) for hemodynamically significant arrhythmias — calcium channel blockers are generally avoided, as they can interact adversely with dantrolene and precipitate hyperkalemia or cardiovascular collapse
Serial arterial blood gases and continuous ECG monitoring guide these interventions, and an arterial line is typically placed to allow frequent sampling without repeated needle sticks during an already labor-intensive resuscitation.
Because myoglobin released from damaged muscle can precipitate in renal tubules and cause acute kidney injury, generous IV fluids and diuresis (targeting urine output above roughly 1–2 mL/kg/hr) are pursued alongside cooling and electrolyte correction, with urine color and output trended as a bedside marker of ongoing rhabdomyolysis.
By this stage, the response typically involves several people working in parallel: one managing the airway and ventilation, one continuing dantrolene doses, one applying cooling measures, one drawing labs and managing lines, and a team leader tracking the overall trend and communicating with the MH hotline. Laboratory studies sent at intervals include arterial blood gas, electrolytes (especially potassium), creatine kinase, coagulation studies (watching for disseminated intravascular coagulation in severe cases), and myoglobin. A structured checklist or the posted MH cart algorithm helps ensure no step — insulin/glucose, calcium, bicarbonate, fluids, urine output monitoring — is missed amid the volume of simultaneous tasks.
Successfully reversing the acute crisis is not the end of MH management. Roughly a quarter of patients experience recrudescence — a recurrence of MH signs after apparent initial control — typically within the first 16 hours, which is why intensive care monitoring continues for at least 24 hours. Once the patient is stable, attention turns to confirming the diagnosis, protecting the patient long-term, and extending testing and counseling to biological family members who share the same genetic risk.
After signs resolve, the patient is transferred to an ICU setting for continuous monitoring of temperature, EtCO₂ (if still intubated), heart rhythm, and repeat laboratory studies for at least 24 hours. Recrudescence — a return of hypermetabolic signs after initial apparent control — occurs in roughly one in five patients, more often in those with larger muscle mass, longer trigger exposure before recognition, or higher initial temperature, and most commonly within the first 16 hours. Because of this risk, dantrolene supply should remain readily available at the bedside, and some protocols include scheduled maintenance dosing for the first 24 hours rather than relying solely on as-needed re-dosing if signs recur.
Serial creatine kinase (CK) and urine myoglobin are trended over the following days — CK typically peaks 12–24 hours after the event and can remain markedly elevated even after clinical signs have resolved, reflecting ongoing muscle injury. Renal function is monitored closely given the risk of myoglobin-associated acute kidney injury, and coagulation studies are followed in patients who had a severe or prolonged crisis, given the risk of disseminated intravascular coagulation. Electrolytes, particularly potassium, are rechecked periodically as cellular integrity is restored and any residual derangements resolve.
Once the patient has recovered, definitive testing is offered to confirm MH susceptibility and to guide anesthetic planning for the future, as well as to identify at-risk relatives before they are ever exposed to a triggering agent.
• Caffeine-halothane contracture test (CHCT), also called the in vitro contracture test (IVCT) in Europe: the gold-standard functional test, requiring a fresh skeletal muscle biopsy exposed to graded caffeine and halothane concentrations to measure contracture response; performed only at specialized MH testing centers • Genetic testing: targeted sequencing of RYR1 (and CACNA1S) for known pathogenic variants; a positive result can confirm susceptibility without biopsy, but a negative result does not rule out MH susceptibility, since many families carry variants not yet catalogued as pathogenic • Family cascade testing: first-degree relatives of a confirmed or clinically suspected MH-susceptible patient are offered genetic counseling and testing, since MH susceptibility is inherited in an autosomal dominant pattern with variable penetrance — a single confirmed case can reveal risk across an extended family tree
Confirmed or clinically suspected MH-susceptible patients and relatives are counseled to enroll with a medical alert registry (such as a MedicAlert bracelet) and to inform any future anesthesia provider of the diagnosis, so that triggering agents are avoided proactively rather than managed reactively.
Every confirmed or clinically suspected MH event should be reported to a national MH registry, and the patient and family should be connected with the MH hotline and a regional MH testing center for genetic counseling — turning a single crisis into protective knowledge for an entire family line.
1. Recognize suspicious signs (rising EtCO₂, tachycardia, rigidity, temperature rise) and stop all triggering agents immediately 2. Call for help; declare "malignant hyperthermia"; call the MH hotline for real-time guidance 3. Hyperventilate with 100% O₂ at high fresh gas flow; switch to TIVA if surgery continues 4. Activate the MH cart; assign dedicated staff to reconstitute dantrolene in parallel 5. Administer dantrolene 2.5 mg/kg IV, repeat every 5–10 minutes titrated to EtCO₂/heart rate/rigidity, commonly to a cumulative 4–10 mg/kg or more 6. Begin active cooling (ice, cold IV fluids, cooling blankets); stop cooling near 38.5°C to avoid overshoot 7. Treat hyperkalemia (insulin/glucose, calcium), correct acidosis (bicarbonate as indicated), and monitor for arrhythmias 8. Ensure brisk urine output and protect renal function against myoglobinuria 9. Transfer to ICU for at least 24 hours of monitoring for recrudescence; trend CK, myoglobin, electrolytes, and renal function 10. Arrange definitive MH testing (CHCT or genetic testing) and family/genetic counseling; register for MedicAlert and MH registries